These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 10203046)

  • 21. Simian immunodeficiency virus (SIV)-specific CTL in cerebrospinal fluid and brains of SIV-infected rhesus macaques.
    von Herrath M; Oldstone MB; Fox HS
    J Immunol; 1995 May; 154(10):5582-9. PubMed ID: 7730657
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mucosal priming of simian immunodeficiency virus-specific cytotoxic T-lymphocyte responses in rhesus macaques by the Salmonella type III secretion antigen delivery system.
    Evans DT; Chen LM; Gillis J; Lin KC; Harty B; Mazzara GP; Donis RO; Mansfield KG; Lifson JD; Desrosiers RC; Galán JE; Johnson RP
    J Virol; 2003 Feb; 77(4):2400-9. PubMed ID: 12551977
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity of hybrid DNA vaccines expressing hepatitis B core particles carrying human and simian immunodeficiency virus epitopes in mice and rhesus macaques.
    Fuller DH; Shipley T; Allen TM; Fuller JT; Wu MS; Horton H; Wilson N; Widera G; Watkins DI
    Virology; 2007 Aug; 364(2):245-55. PubMed ID: 17428516
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The kinetics of specific immune responses in rhesus monkeys inoculated with live recombinant BCG expressing SIV Gag, Pol, Env, and Nef proteins.
    Leung NJ; Aldovini A; Young R; Jarvis MA; Smith JM; Meyer D; Anderson DE; Carlos MP; Gardner MB; Torres JV
    Virology; 2000 Mar; 268(1):94-103. PubMed ID: 10683331
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction of mucosal protection against primary, heterologous simian immunodeficiency virus by a DNA vaccine.
    Fuller DH; Rajakumar PA; Wilson LA; Trichel AM; Fuller JT; Shipley T; Wu MS; Weis K; Rinaldo CR; Haynes JR; Murphey-Corb M
    J Virol; 2002 Apr; 76(7):3309-17. PubMed ID: 11884556
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Simian immunodeficiency virus (SIV)-specific CD8+ cytotoxic T lymphocyte responses of naive and vaccinated cynomolgus macaques infected with SIVmac32H(J5): quantitative analysis by in vitro antigenic stimulation.
    Geretti AM; Hulskotte EG; Dings ME; van Baalen CA; van Amerongen G; Osterhaus AD
    Vaccine; 1997 Aug; 15(11):1269-75. PubMed ID: 9286055
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Simian Immunodeficiency Virus (SIV)-Specific Chimeric Antigen Receptor-T Cells Engineered to Target B Cell Follicles and Suppress SIV Replication.
    Haran KP; Hajduczki A; Pampusch MS; Mwakalundwa G; Vargas-Inchaustegui DA; Rakasz EG; Connick E; Berger EA; Skinner PJ
    Front Immunol; 2018; 9():492. PubMed ID: 29616024
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of seventeen new simian immunodeficiency virus-derived CD8+ T cell epitopes restricted by the high frequency molecule, Mamu-A*02, and potential escape from CTL recognition.
    Loffredo JT; Sidney J; Wojewoda C; Dodds E; Reynolds MR; Napoé G; Mothé BR; O'Connor DH; Wilson NA; Watkins DI; Sette A
    J Immunol; 2004 Oct; 173(8):5064-76. PubMed ID: 15470050
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Repeated exposure of rhesus macaques to low doses of simian immunodeficiency virus (SIV) did not protect them against the consequences of a high-dose SIV challenge.
    Dittmer U; Stahl-Hennig C; Coulibaly C; Nisslein T; Lüke W; Fuchs D; Bodemer W; Petry H; Hunsmann G
    J Gen Virol; 1995 Jun; 76 ( Pt 6)():1307-15. PubMed ID: 7782761
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Simian immunodeficiency virus-specific cytotoxic T lymphocytes in rhesus monkeys: characterization and vaccine induction.
    Letvin NL; Miller MD; Shen L; Chen ZW; Yasutomi Y
    Semin Immunol; 1993 Jun; 5(3):215-23. PubMed ID: 8394161
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Simian immunodeficiency virus (SIV)-specific CTL are present in large numbers in livers of SIV-infected rhesus monkeys.
    Schmitz JE; Kuroda MJ; Veazey RS; Seth A; Taylor WM; Nickerson CE; Lifton MA; Dailey PJ; Forman MA; Racz P; Tenner-Racz K; Letvin NL
    J Immunol; 2000 Jun; 164(11):6015-9. PubMed ID: 10820285
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recombinant canarypox vaccine-elicited CTL specific for dominant and subdominant simian immunodeficiency virus epitopes in rhesus monkeys.
    Santra S; Schmitz JE; Kuroda MJ; Lifton MA; Nickerson CE; Lord CI; Pal R; Franchini G; Letvin NL
    J Immunol; 2002 Feb; 168(4):1847-53. PubMed ID: 11823518
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytotoxic T-lymphocyte escape monitoring in simian immunodeficiency virus vaccine challenge studies.
    O'Connor DH; Allen TM; Watkins DI
    DNA Cell Biol; 2002 Sep; 21(9):659-64. PubMed ID: 12396608
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multispecific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239.
    Vogel TU; Reynolds MR; Fuller DH; Vielhuber K; Shipley T; Fuller JT; Kunstman KJ; Sutter G; Marthas ML; Erfle V; Wolinsky SM; Wang C; Allison DB; Rud EW; Wilson N; Montefiori D; Altman JD; Watkins DI
    J Virol; 2003 Dec; 77(24):13348-60. PubMed ID: 14645590
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimization of a peptide-based protocol employing IL-7 for in vitro restimulation of human cytotoxic T lymphocyte precursors.
    Lalvani A; Dong T; Ogg G; Patham AA; Newell H; Hill AV; McMichael AJ; Rowland-Jones S
    J Immunol Methods; 1997 Dec; 210(1):65-77. PubMed ID: 9502585
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cell-mediated immune response of macaques immunized with low doses of simian immunodeficiency virus (SIV).
    Dittmer U; Spring M; Petry H; Nisslein T; Rieckmann P; Lüke W; Stahl-Hennig C; Hunsmann G; Bodemer W
    J Biotechnol; 1996 Jan; 44(1-3):105-10. PubMed ID: 8717393
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structural constraints on viral escape from HIV- and SIV-specific cytotoxic T-lymphocytes.
    Peyerl FW; Barouch DH; Letvin NL
    Viral Immunol; 2004; 17(2):144-51. PubMed ID: 15279695
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vaccination with CTL epitopes that escape: an alternative approach to HIV vaccine development?
    O'Connor D; Allen T; Watkins DI
    Immunol Lett; 2001 Nov; 79(1-2):77-84. PubMed ID: 11595292
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vaccine protection against functional CTL abnormalities in simian human immunodeficiency virus-infected rhesus monkeys.
    McKay PF; Schmitz JE; Barouch DH; Kuroda MJ; Lifton MA; Nickerson CE; Gorgone DA; Letvin NL
    J Immunol; 2002 Jan; 168(1):332-7. PubMed ID: 11751978
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes.
    Barouch DH; Kunstman J; Kuroda MJ; Schmitz JE; Santra S; Peyerl FW; Krivulka GR; Beaudry K; Lifton MA; Gorgone DA; Montefiori DC; Lewis MG; Wolinsky SM; Letvin NL
    Nature; 2002 Jan; 415(6869):335-9. PubMed ID: 11797012
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.